A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis



Status:Completed
Conditions:Colitis, Colitis, Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - Any
Updated:1/6/2019
Start Date:November 15, 2013
End Date:December 5, 2015

Use our guide to learn which trials are right for you!

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects With Moderately to Severely Active Ulcerative Colitis

The purpose of the study is to evaluate dose response of JNJ-54781532 in participants with
moderately to severely active ulcerative colitis (UC).

This is a Phase 2b, multicenter, randomized (the study medication is assigned by chance),
double-blind (neither physician nor participant knows the treatment that the participant
receives), placebo-controlled (an inactive substance that is compared with a medication to
test whether the medication has a real effect in a clinical study), parallel-group (each
group of participants will be treated at the same time), dose-response study (a study to
evaluate response to different dosages of study medication) of oral tablets of JNJ-54781532
in adult participants with moderately to severely active UC. Approximately 220 participants
will be randomized in a 1:1:1:1:1 ratio to 1 of 5 treatment groups at Week 0 (placebo;
JNJ-54781532 25 mg once daily; JNJ-54781532 75 mg once daily; JNJ-54781532 150 mg once daily;
and JNJ-54781532 75 mg twice daily) to receive their randomized dosage of study medication
through Week 8 and will be assessed for clinical response at Week 8. Participants who achieve
clinical response at Week 8 will continue to receive their original randomized dosage of
study medication through Week 32. Participants who do not achieve clinical response at Week 8
will be treated as follows: participants originally randomized to placebo will receive
JNJ-54781532 150 mg once daily through Week 16; participants originally randomized to
JNJ-54781532 will continue to receive their original randomized dosage of JNJ-54781532
through Week 16. Participants who were not in clinical response at Week 8 and do not achieve
a partial Mayo score response (a decrease from baseline in the partial Mayo score by ≥3
points) at Week 16 will be discontinued from study medication; and those who achieve a
partial Mayo score response at Week 16 can continue receiving JNJ 54781532 through Week 32.
Participants will be evaluated for safety (adverse events) up to Week 36 (ie, 4 weeks after
the last dose of study medication). The maximum study duration for each participant will be
approximately 44 weeks (including maximum screening period).

Inclusion Criteria:

- Have a clinical diagnosis of ulcerative colitis (UC) at least 3 months prior to
screening

- Have moderately to severely active UC, defined as a baseline (Week 0) Mayo score of 6
to 12; including an endoscopy sub score greater than or equal to 2 as determined by a
central read of the video endoscopy

- Current treatment with oral corticosteroids or have a history of failure to respond
to, or tolerate, at least 1 of the following therapies oral corticosteroids (including
budesonide), 6-mercaptopurine (6-MP), azathioprine (AZA), or anti- tumor necrosis
factor therapy or be corticosteroid dependent (ie, an inability to successfully taper
corticosteroids without a return of the symptoms of UC)

- Must discontinue 6-MP/AZA for at least 1 week before the first dose of study
medication

Exclusion Criteria:

- At imminent risk for colectomy

- Have ulcerative colitis limited to the rectum only or to less than 20 centimeter of
the colon

- Presence of a stoma

- Presence or history of a fistula

- History or current diagnosis of active or latent tuberculosis; human immunodeficiency
virus; hepatitis C virus or hepatitis B virus infection; have had more than 1 herpes
zoster infection or have had any diagnosis of disseminated herpes zoster

- Previous treatment with a janus kinase inhibitor (eg, tofacitinib)
We found this trial at
16
sites
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Bankstown,
Click here to add this to my saved trials
?
mi
from
Chesapeake, VA
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Egg Harbor Township, New Jersey 08234
?
mi
from
Egg Harbor Township, NJ
Click here to add this to my saved trials
?
mi
from
Fairfax, VA
Click here to add this to my saved trials
?
mi
from
Germantown, TN
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
Lima, OH
Click here to add this to my saved trials
?
mi
from
Norman, OK
Click here to add this to my saved trials
Salisbury, North Carolina 28144
?
mi
from
Salisbury, NC
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Thornton, CO
Click here to add this to my saved trials
?
mi
from
Tupelo, MS
Click here to add this to my saved trials